The International Breast Cancer Study Group (IBCSG), Breast
International Group (BIG), and Merck, known as MSD outside the United
States and Canada, today announced the opening of the PANACEA study, a
global collaborative study exploring a new way to treat HER2+ breast
cancer that has become resistant to the current standard of care.
for International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer investment picks